Nothing said here yet.
to join the conversation.
| Sahin UgurChief Executive Officer | Sell | 36,209 | $3.5M | Fri, Oct 9 |
| Sahin UgurChief Executive Officer | Sell | 27,000 | $2.5M | Thu, Oct 8 |
| Sahin UgurChief Executive Officer | Sell | 24,000 | $2.3M | Wed, Oct 7 |
| Sahin UgurChief Executive Officer | Sell | 21,000 | $2.0M | Tue, Oct 6 |
| Sahin UgurChief Executive Officer | Sell | 72,000 | $7.0M | Mon, Oct 5 |
| Sahin UgurChief Executive Officer | Sell | 17,000 | $1.6M | Fri, Oct 2 |
| Sahin UgurChief Executive Officer | Sell | 17,000 | $1.7M | Thu, Oct 1 |
| Sahin UgurChief Executive Officer | Sell | 32,000 | $3.1M | Wed, Sep 30 |
| Sahin UgurChief Executive Officer | Sell | 34,000 | $3.3M | Tue, Sep 29 |
| Sahin UgurChief Executive Officer | Sell | 34,000 | $3.3M | Mon, Sep 28 |
| Sahin UgurChief Executive Officer | Sell | 27,000 | $2.7M | Fri, Sep 25 |
| Sahin UgurChief Executive Officer | Sell | 39,000 | $3.9M | Thu, Sep 24 |
BioNTech (NasdaqGS:BNTX) and DualityBio reported positive topline results from the DYNASTY-Breast02 Phase 3 trial in HR+/HER2-low metastatic breast cancer, including a statistically significant improvement in progression-free survival.
Moderna stock is surging even after an analyst cited its 636% yearly gain as reason enough to step back, and the real question is whether Wall Street is pricing in a cancer breakthrough that has yet to prove itself outside one tumor type.
Moderna's personalized melanoma vaccine cleared its primary hurdle in a late-stage trial, yet shares are sinking fast.
BioNTech (NasdaqGS:BNTX) just expanded its oncology pipeline by announcing new Phase 2 data for pumitamig plus docetaxel in metastatic non small cell lung cancer, alongside a new Phase 3 collaboration in triple negative breast cancer.
BioNTech (NasdaqGS:BNTX) and Gilead Sciences agreed to a clinical trial collaboration to study pumitamig with sacituzumab govitecan in first-line metastatic triple-negative breast cancer.
BioNTech has seen its share price move around in recent years, and with the focus increasingly on its oncology pipeline, the key question now is whether the current valuation is still aligned with the revenue base behind it.